Drugs that contain Lesinurad

1. Drug name - ZURAMPIC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8003681 IRONWOOD PHARMS INC 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester
Aug, 2025

(2 years from now)

US8546436 IRONWOOD PHARMS INC Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof
Feb, 2032

(9 years from now)

CN101083987B IRONWOOD PHARMS INC S-Triazolyl Alpha-Mercaptoacetanildes As Inhibitors Of Hiv Reverse Transcriptase
Aug, 2025

(2 years from now)

CN101817793B IRONWOOD PHARMS INC S-Triazolyl Alpha-Mercaptoacetanildes As Inhibitors Of Hiv Reverse Transcriptase
Aug, 2025

(2 years from now)

CN101817793A IRONWOOD PHARMS INC S-Triazolyl A-Mercaptoacet Anilides As Hiv Reverse Transcriptase Inhibitor
Aug, 2025

(2 years from now)

CN101083987A IRONWOOD PHARMS INC S - Triazolyl A - Hydrosulphonyl Acetanilide As Hiv Revertase Inhibitor
Aug, 2025

(2 years from now)

CN103298796B IRONWOOD PHARMS INC Polymorphic Forms Of 2 - (5 - -4-(4 - -1 - Yl) -4H-1, 2, 4-Triazole - -3 - Puropose) Acetic Acid And The Use Thereof
Dec, 2031

(9 years from now)

CN103298796A IRONWOOD PHARMS INC Polymorphic Forms Of 2-(5-Bromo-4-(4-Cyclopropylnaphthalen-1-Yl)-4-1,2,4-Triazol-3- Ylthio) Acetic Acid And Uses Thereof
Dec, 2031

(9 years from now)

IN262812B IRONWOOD PHARMS INC 2-(5-Bromo-4-(4-Cyclopropylnaphthalen-1-Yl)-4H-1,2,4-Triazol-3-Ylthio)Acetic Acid, Methyl Ester, And 2-Chloro-4-Sulfamoylphenyl Amide
Aug, 2025

(2 years from now)

IN200701232P4 IRONWOOD PHARMS INC 2-(5-Bromo-4-(4-Cyclopropylnaphthalen-1-Yl)-4H-1,2,4-Triazol-3-Ylthio)Acetic Acid And Methyl Ester
Aug, 2025

(2 years from now)

EP2402011A1 IRONWOOD PHARMS INC S-Triazolyl Alpha-Mercaptoacetanilides As Inhibitors Of Hiv Reverse Transcriptase
Aug, 2025

(2 years from now)

EP1789039A2 IRONWOOD PHARMS INC S-Triazolyl Alpha -Mercaptoacetanildes As Inhibitors Of Hiv Reverse Transcriptase
Aug, 2025

(2 years from now)

EP1789039A4 IRONWOOD PHARMS INC S-Triazolyl Alpha -Mercaptoacetanildes As Inhibitors Of Hiv Reverse Transcriptase
Aug, 2025

(2 years from now)

EP2402011B1 IRONWOOD PHARMS INC S-Triazolyl Alpha-Mercaptoacetanilides As Inhibitors Of Hiv Reverse Transcriptase
Aug, 2025

(2 years from now)

EP1789039B1 IRONWOOD PHARMS INC S-Triazolyl Alpha -Mercaptoacetanildes As Inhibitors Of Hiv Reverse Transcriptase
Aug, 2025

(2 years from now)

EP2135608B1 IRONWOOD PHARMS INC S-Triazolyl Alpha -Mercaptoacetanilides As Inhibitors Of Hiv Reverse Transcriptase
Aug, 2025

(2 years from now)

EP2135608A1 IRONWOOD PHARMS INC S-Triazolyl Alpha -Mercaptoacetanilides As Inhibitors Of Hiv Reverse Transcriptase
Aug, 2025

(2 years from now)

EP2135608B8 IRONWOOD PHARMS INC S-Triazolyl Alpha -Mercaptoacetanilides As Inhibitors Of Hiv Reverse Transcriptase
Aug, 2025

(2 years from now)

EP2658846A2 IRONWOOD PHARMS INC Polymorphic Forms Of 2-(5-Bromo-4-(4-Cyclopropylnaphthalen-1-Yl)-4H-1,2,4-Triazol-3-Ylthio) Acetic Acid And Uses Thereof
Dec, 2031

(9 years from now)

EP2658846B1 IRONWOOD PHARMS INC Polymorphic Forms Of 2-(5-Bromo-4-(4-Cyclopropylnaphthalen-1-Yl)-4H-1,2,4-Triazol-3-Ylthio) Acetic Acid And Uses Thereof
Dec, 2031

(9 years from now)

EP2658846A4 IRONWOOD PHARMS INC Polymorphic Forms Of 2-(5-Bromo-4-(4-Cyclopropylnaphthalen-1-Yl)-4H-1,2,4-Triazol-3-Ylthio) Acetic Acid And Uses Thereof
Dec, 2031

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8283369 IRONWOOD PHARMS INC Compounds and compositions and methods of use Nov, 2028

(6 years from now)

US8357713 IRONWOOD PHARMS INC Compounds and compositions and methods of use Nov, 2028

(6 years from now)

US10183012 IRONWOOD PHARMS INC Compounds and compositions and methods of use Nov, 2028

(6 years from now)

US8546437 IRONWOOD PHARMS INC Compounds and compositions and methods of use Apr, 2029

(6 years from now)

US8084483 IRONWOOD PHARMS INC Compounds and compositions and methods of use Aug, 2029

(6 years from now)

US9216179 IRONWOOD PHARMS INC Treatment of gout and hyperuricemia Aug, 2031

(8 years from now)

US9956205 IRONWOOD PHARMS INC Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof Dec, 2031

(9 years from now)

Treatment: Achieving a therapeutic benefit in a subject with gout; treatment of gout; Reduction of serum uric acid levels; treatment of hyperuricemia; treatment of gout; Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone; Treatment of hyperuricemia; Reduction of serum uric acid levels; Coadministering with allopurinol to reduce serum uric acid (sua) below 4 mg/dl; below 6mg/dl in patients having uric acid deposits; and/or below 6mg/dl with sua intraday change more than 50% and/or adverse event rate less than 15%

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
200MG TABLET;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.